PRLX93936 rastin analogue manufacturers
- PRLX-93936
-
- $55.00
-
2026-07-17
- CAS:903499-49-0
- Purity:
- Supply Ability: 10g
|
| | PRLX93936 rastin analogue Basic information |
| Product Name: | PRLX93936 rastin analogue | | Synonyms: | PRLX93936 rastin analogue;4(3H)-Quinazolinone, 3-(2-ethoxyphenyl)-2-(1-piperazinylmethyl)-;PRLX93936,PRLX 93936;3-(2-ethoxyphenyl)-2-(1-piperazinylmethyl)-4(3H)-quinazolinone;PRLX-93936;3-(2-Ethoxyphenyl)-2-(piperazin-1-ylmethyl)quinazolin-4(3H)-one , PRLX-93936 | | CAS: | 903499-49-0 | | MF: | C21H24N4O2 | | MW: | 364.44 | | EINECS: | | | Product Categories: | | | Mol File: | 903499-49-0.mol |  |
| | PRLX93936 rastin analogue Chemical Properties |
| Boiling point | 545.5±60.0 °C(Predicted) | | density | 1.25±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: Soluble | | form | A solid | | pka | 9.01±0.10(Predicted) |
| | PRLX93936 rastin analogue Usage And Synthesis |
| Uses | PRLX-93936 dihydrochloride (Compound 16) is a HIF-1α inhibitor with anticancer activity. PRLX-93936 can inhibit the activated Ras pathway and can be used in the study of relapsed or refractory multiple myeloma[1][2]. | | References | [1] Huang W, et al. Synthesis and evaluation of quinazolin-4-ones as hypoxia-inducible factor-1α inhibitors. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5239-43. DOI:10.1016/j.bmcl.2011.07.043
[2] Voorhees P M, et al. An open-label, dose escalation, multi-center phase 1 study of PRLX 93936, an agent synthetically active against the activated ras pathway, in the treatment of relapsed or relapsed and refractory multiple myeloma[J]. Blood, 2014, 124(21): 2140. |
| | PRLX93936 rastin analogue Preparation Products And Raw materials |
|